98%
921
2 minutes
20
Conventional bone grafts face challenges in clinical applications, including donor shortages, immunological rejection, and mismatched degradation rates. This work introduces a porous microsphere scaffold loaded with self-assembled tea polyphenolic‑magnesium biomineralized nanoparticles to synergistically enhance antibacterial and osteogenic properties through a dual-factor spatiotemporal controlled release approach. Employing a biomimetic mineralization mechanism that mimics natural bone mineral formation, these nanoparticles integrate tea polyphenols with magnesium ions. This method achieves pH-responsive release kinetics: the antimicrobial component releases more effectively in mildly acidic infection microenvironments, while the mineral phase acts as a buffer against burst release, maintaining consistent local medication concentrations. Complementing this sustained-release behavior, polytrimethylene carbonate microspheres degrade via surface erosion, thereby extending therapeutic efficacy through dual "degradation-release" regulation. In vitro studies demonstrated effective eradication of methicillin-resistant Staphylococcus aureus biofilms, along with significant enhancement of osteoblast proliferation, differentiation, and mineralization activities by the scaffold. The scaffold's porous structure mimics cancellous bone, providing an appropriate compression modulus (∼195 MPa), supporting cell infiltration, and facilitating nutrient transport, thereby simulating the three-dimensional architecture of native bone tissue. Moreover, the scaffold modulates macrophage polarization toward the M2 phenotype and stimulates the secretion of anti-inflammatory cytokines (IL-37, IL-10), thereby fostering a favorable bone immune microenvironment. This work establishes a multifunctional bone tissue engineering platform by integrating spatiotemporal delivery (dual controlled release) with biomimetic mineral stabilization. By addressing infection control, promoting bone regeneration, and modulating immune responses simultaneously, this scaffold presents a promising solution for complicated infected bone defects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jconrel.2025.114097 | DOI Listing |
Clin Anat
September 2025
Department of Communication Disorders and Sciences, Rush University Medical Center, Chicago, Illinois, USA.
This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as gleaned from death certificates. HFI is an irregular bony overgrowth of the endocranial surface of the frontal bone.
View Article and Find Full Text PDFDan Med J
August 2025
Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital.
Introduction: Cardiac amyloidosis is an underdiagnosed disease, and its prevalence is probably higher than previously estimated. We aimed to investigate the effect of introducing a systemic diagnostic algorithm for cardiac amyloidosis in clinical practice.
Methods: A systematic diagnostic algorithm was developed and clinically applied in two hospitals in Eastern Denmark.
Eur J Case Rep Intern Med
September 2025
Respiratory Department, University Hospital Limerick, Limerick, Ireland.
Unlabelled: B-cell lymphomas are highly aggressive forms of lymphoma that commonly present with lymphadenopathy, systemic "B" symptoms, or organ involvement making them easy to recognize; however, a small percentage of B-cell lymphomas can present without any typical symptoms or evidence of lymphadenopathy, resulting in delayed recognition and management. Isolated thrombocytopenia without anaemia or leukopenia is an unusual presentation of B cell lymphomas and may be misdiagnosed as immune thrombocytopenia (ITP). Given the rarity of this presentation, we wish to report a case of a 76-year-old female who presented with palpitations, shortness of breath, and recurrent chest infections.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
General medicine department, Universidad de Cartagena, Cartagena, Colombia.
Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.
Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.
Eur J Case Rep Intern Med
August 2025
Division of Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA.
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.
View Article and Find Full Text PDF